Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 9/2014

01-09-2014 | Original Article

Potential of hybrid 18F-fluorocholine PET/MRI for prostate cancer imaging

Authors: Thomas de Perrot, Olivier Rager, Max Scheffler, Martin Lord, Marc Pusztaszeri, Christophe Iselin, Osman Ratib, Jean-Paul Vallee

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2014

Login to get access

Abstract

Purpose

To report the first results of hybrid 18F-fluorocholine PET/MRI imaging for the detection of prostate cancer.

Methods

This analysis included 26 consecutive patients scheduled for prostate PET/MRI before radical prostatectomy. The examinations were performed on a hybrid whole-body PET/MRI scanner. The MR acquisitions which included T2-weighted, diffusion-weighted and dynamic contrast-enhanced sequences were followed during the same session by whole-body PET scans. Parametric maps were constructed to measure normalized T2-weighted intensity (nT2), apparent diffusion coefficient (ADC), volume transfer constant (K trans), extravascular extracellular volume fraction (v e) and standardized uptake values (SUV). With pathology as the gold standard, ROC curves were calculated using logistic regression for each parameter and for the best combination with and without PET to obtain a MR model versus a PETMR model.

Results

Of the 26 patients initially selected, 3 were excluded due to absence of an endorectal coil (2 patients) or prosthesis artefacts (1 patient). In the whole prostate, the area under the curve (AUC) for SUVmax, ADC, nT2, K trans and v e were 0.762, 0.756, 0.685, 0.611 and 0.529 with a best threshold at 3.044 for SUVmax and 1.075 × 10−3 mm2/s for ADC. The anatomical distinction between the transition zone and the peripheral zone showed the potential of the adjunctive use of PET. In the peripheral zone, the AUC of 0.893 for the PETMR model was significantly greater (p = 0.0402) than the AUC of 0.84 for the MR model only. In the whole prostate, no relevant correlation was observed between ADC and SUVmax. The SUVmax was not affected by the Gleason score.

Conclusion

The performance of a hybrid whole-body 18F-fluorocholine PET/MRI scan in the same session combined with a prostatic MR examination did not interfere with the diagnostic accuracy of the MR sequences. The registration of the PET data and the T2 anatomical MR sequence data allowed precise localization of hypermetabolic foci in the prostate. While in the transition zone the adenomatous hyperplasia interfered with cancer detection by PET, the quantitative analysis tool performed well for cancer detection in the peripheral zone.
Appendix
Available only for authorised users
Literature
3.
go back to reference Yakar D, Debats OA, Bomers JG, Schouten MG, Vos PC, van Lin E, et al. Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J Magn Reson Imaging. 2012;35:20–31. doi:10.1002/jmri.22790.PubMedCrossRef Yakar D, Debats OA, Bomers JG, Schouten MG, Vos PC, van Lin E, et al. Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J Magn Reson Imaging. 2012;35:20–31. doi:10.​1002/​jmri.​22790.PubMedCrossRef
6.
go back to reference Steiner C, Vees H, Zaidi H, Wissmeyer M, Berrebi O, Kossovsky MP, et al. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin Nucl Med. 2009;48:1–9; quiz N2–3. Steiner C, Vees H, Zaidi H, Wissmeyer M, Berrebi O, Kossovsky MP, et al. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin Nucl Med. 2009;48:1–9; quiz N2–3.
7.
go back to reference Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18–23. doi:10.1007/s00259-007-0581-4.PubMedCrossRef Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18–23. doi:10.​1007/​s00259-007-0581-4.PubMedCrossRef
8.
go back to reference Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394–400. doi:10.2967/jnumed.108.061507.PubMedCrossRef Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394–400. doi:10.​2967/​jnumed.​108.​061507.PubMedCrossRef
9.
11.
13.
go back to reference Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008;54:392–401. doi:10.1016/j.eururo.2008.04.030.PubMedCrossRef Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008;54:392–401. doi:10.​1016/​j.​eururo.​2008.​04.​030.PubMedCrossRef
14.
go back to reference Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925–33. doi:10.1148/radiol.09090413.PubMedCrossRef Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925–33. doi:10.​1148/​radiol.​09090413.PubMedCrossRef
15.
go back to reference Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642–9.PubMed Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642–9.PubMed
16.
go back to reference Bundschuh RA, Wendl CM, Weirich G, Eiber M, Souvatzoglou M, Treiber U, et al. Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging. 2013;40:824–31. doi:10.1007/s00259-013-2345-7.PubMedCrossRef Bundschuh RA, Wendl CM, Weirich G, Eiber M, Souvatzoglou M, Treiber U, et al. Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging. 2013;40:824–31. doi:10.​1007/​s00259-013-2345-7.PubMedCrossRef
18.
go back to reference Van den Bergh L, Koole M, Isebaert S, Joniau S, Deroose CM, Oyen R, et al. Is there an additional value of (11)C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? Int J Radiat Oncol Biol Phys. 2012;83:1486–92. doi:10.1016/j.ijrobp.2011.10.046.PubMedCrossRef Van den Bergh L, Koole M, Isebaert S, Joniau S, Deroose CM, Oyen R, et al. Is there an additional value of (11)C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? Int J Radiat Oncol Biol Phys. 2012;83:1486–92. doi:10.​1016/​j.​ijrobp.​2011.​10.​046.PubMedCrossRef
20.
go back to reference Schulz V, Torres-Espallardo I, Renisch S, Hu Z, Ojha N, Bornert P, et al. Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data. Eur J Nucl Med Mol Imaging. 2011;38:138–52. doi:10.1007/s00259-010-1603-1.PubMedCrossRef Schulz V, Torres-Espallardo I, Renisch S, Hu Z, Ojha N, Bornert P, et al. Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data. Eur J Nucl Med Mol Imaging. 2011;38:138–52. doi:10.​1007/​s00259-010-1603-1.PubMedCrossRef
21.
go back to reference Tofts PS, Kermode AG. Measurement of the blood–brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991;17:357–67.PubMedCrossRef Tofts PS, Kermode AG. Measurement of the blood–brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991;17:357–67.PubMedCrossRef
22.
go back to reference Fritz-Hansen T, Rostrup E, Larsson HB, Sondergaard L, Ring P, Henriksen O. Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitative perfusion imaging. Magn Reson Med. 1996;36:225–31.PubMedCrossRef Fritz-Hansen T, Rostrup E, Larsson HB, Sondergaard L, Ring P, Henriksen O. Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitative perfusion imaging. Magn Reson Med. 1996;36:225–31.PubMedCrossRef
24.
go back to reference Whitcher B, Schmid VJ. Quantitative analysis of dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging for oncology in R. J Stat Softw. 2011;44:1–29. Whitcher B, Schmid VJ. Quantitative analysis of dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging for oncology in R. J Stat Softw. 2011;44:1–29.
25.
go back to reference Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715–24.PubMedCrossRef Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715–24.PubMedCrossRef
28.
go back to reference Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2009;30:327–34. doi:10.1002/jmri.21824.PubMedCrossRef Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2009;30:327–34. doi:10.​1002/​jmri.​21824.PubMedCrossRef
30.
go back to reference Kim JH, Kim JK, Park BW, Kim N, Cho KS. Apparent diffusion coefficient: prostate cancer versus noncancerous tissue according to anatomical region. J Magn Reson Imaging. 2008;28:1173–9. doi:10.1002/jmri.21513.PubMedCrossRef Kim JH, Kim JK, Park BW, Kim N, Cho KS. Apparent diffusion coefficient: prostate cancer versus noncancerous tissue according to anatomical region. J Magn Reson Imaging. 2008;28:1173–9. doi:10.​1002/​jmri.​21513.PubMedCrossRef
31.
go back to reference Kitajima K, Takahashi S, Ueno Y, Yoshikawa T, Ohno Y, Obara M, et al. Clinical utility of apparent diffusion coefficient values obtained using high b-value when diagnosing prostate cancer using 3 tesla MRI: comparison between ultra-high b-value (2000 s/mm2) and standard high b-value (1000 s/mm2). J Magn Reson Imaging . 2012;36:198–205. doi:10.1002/jmri.23627.PubMedCrossRef Kitajima K, Takahashi S, Ueno Y, Yoshikawa T, Ohno Y, Obara M, et al. Clinical utility of apparent diffusion coefficient values obtained using high b-value when diagnosing prostate cancer using 3 tesla MRI: comparison between ultra-high b-value (2000 s/mm2) and standard high b-value (1000 s/mm2). J Magn Reson Imaging . 2012;36:198–205. doi:10.​1002/​jmri.​23627.PubMedCrossRef
33.
go back to reference Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, et al. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1492–5. doi:10.1007/s00259-002-0885-3.PubMedCrossRef Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, et al. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1492–5. doi:10.​1007/​s00259-002-0885-3.PubMedCrossRef
34.
go back to reference Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli 2nd JF. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol. 2010;194:W316–22. doi:10.2214/AJR.09.2651.PubMedCrossRef Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli 2nd JF. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol. 2010;194:W316–22. doi:10.​2214/​AJR.​09.​2651.PubMedCrossRef
35.
go back to reference Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging. 2005;32:668–73. doi:10.1007/s00259-004-1741-4.PubMedCrossRef Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging. 2005;32:668–73. doi:10.​1007/​s00259-004-1741-4.PubMedCrossRef
36.
go back to reference Verma S, Rajesh A, Morales H, Lemen L, Bills G, Delworth M, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol. 2011;196:374–81. doi:10.2214/AJR.10.4441.PubMedCrossRef Verma S, Rajesh A, Morales H, Lemen L, Bills G, Delworth M, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol. 2011;196:374–81. doi:10.​2214/​AJR.​10.​4441.PubMedCrossRef
38.
go back to reference Somford DM, Hambrock T, de Kaa CA H-v, Futterer JJ, van Oort IM, van Basten JP, et al. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a gleason score ≤3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol. 2012;47:153–8. doi:10.1097/RLI.0b013e31823ea1f0.PubMed Somford DM, Hambrock T, de Kaa CA H-v, Futterer JJ, van Oort IM, van Basten JP, et al. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a gleason score ≤3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol. 2012;47:153–8. doi:10.​1097/​RLI.​0b013e31823ea1f0​.PubMed
42.
go back to reference Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449–58. doi:10.1148/radiol.2412051866.PubMedCrossRef Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449–58. doi:10.​1148/​radiol.​2412051866.PubMedCrossRef
43.
go back to reference Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011;197:1382–90. doi:10.2214/AJR.11.6861.PubMedCrossRef Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011;197:1382–90. doi:10.​2214/​AJR.​11.​6861.PubMedCrossRef
44.
go back to reference Reducindo I, Arce-Santana E, Campos-Delgado DU, Vigueras-Gomez F. Non-rigid multimodal image registration based on local variability measures and optical flow. Conf Proc IEEE Eng Med Biol Soc. 2012;2012:1133–6. doi:10.1109/EMBC.2012.6346135.PubMed Reducindo I, Arce-Santana E, Campos-Delgado DU, Vigueras-Gomez F. Non-rigid multimodal image registration based on local variability measures and optical flow. Conf Proc IEEE Eng Med Biol Soc. 2012;2012:1133–6. doi:10.​1109/​EMBC.​2012.​6346135.PubMed
46.
go back to reference Chang JH, Lim Joon D, Lee ST, Gong SJ, Anderson NJ, Scott AM, et al. Intensity modulated radiation therapy dose painting for localized prostate cancer using 11C-choline positron emission tomography scans. Int J Radiat Oncol Biol Phys. 2012;83:e691–6. doi:10.1016/j.ijrobp.2012.01.087.PubMedCrossRef Chang JH, Lim Joon D, Lee ST, Gong SJ, Anderson NJ, Scott AM, et al. Intensity modulated radiation therapy dose painting for localized prostate cancer using 11C-choline positron emission tomography scans. Int J Radiat Oncol Biol Phys. 2012;83:e691–6. doi:10.​1016/​j.​ijrobp.​2012.​01.​087.PubMedCrossRef
Metadata
Title
Potential of hybrid 18F-fluorocholine PET/MRI for prostate cancer imaging
Authors
Thomas de Perrot
Olivier Rager
Max Scheffler
Martin Lord
Marc Pusztaszeri
Christophe Iselin
Osman Ratib
Jean-Paul Vallee
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-014-2786-7

Other articles of this Issue 9/2014

European Journal of Nuclear Medicine and Molecular Imaging 9/2014 Go to the issue